Company

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody
Auto-immuneBioPartners X

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody

BioPartners X announced that it has entered into a technology transfer agreement with the Hospital of Dermatology, Chinese Academy of Medical Sciences (CAMS) for an innovative CD132‑targeting monoclonal antibody, with…

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Antengene and MSD Collaborate on ATG-022 for Advanced Solid Tumors
AntengeneCombination therapy

Antengene and MSD Collaborate on ATG-022 for Advanced Solid Tumors

3SBio Registers Phase III Study for SSGJ-707 in Advanced NSCLC
3SBioCancer

3SBio Registers Phase III Study for SSGJ-707 in Advanced NSCLC

Ascletis Pharma Initiates ASC47-103 Study in US for Obesity Treatment
Ascletis PharmaClinical trial approval / initiation

Ascletis Pharma Initiates ASC47-103 Study in US for Obesity Treatment

Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets
CancerLenis

Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets

Show More